Selling into a wave of new capacity being built by others: management describes its customers' own build-out spending as
The model's full reasoning — Q4 2021 call → NOWe need to determine if management explains momentum and near-term trajectory chiefly by pointing to a wave of new building/equipping/capacity-creation by other parties, for which the company already supplies part, and that this build-out is early/intensifying. Let's analyze the transcript. The company is SOPHiA GENETICS, a data-driven medicine platform. They talk about six pillars: customer adoption, utilization, innovation, partnerships, biopharma, operational excellence. Key points: They mention customers adopting their platform, increasing utilization, new products like HRD, CarePath, partnerships with GE, Ambry, AstraZeneca. They talk about biopharma opportunity. Is there a description of others building new capacity? They mention hospitals, labs, biopharma companies. But is it about creating new productive capability? They talk about customers adopting their platform, which is more like buying software. They mention "land and expand" strategy, increasing utilization. They mention "new customer adoption" and "network expansion." They mention "onboarding clinical customers" and "signed agreements with Tier 1 institutions." They mention "reference labs and central labs" in the U.S. They mention "Ambry Genetics" partnership. They mention "HRD testing" demand. They mention "DEEP-Lung-IV study" with sites signing up. They mention "biopharma" with 18 of top 20 pharma in discussions. But is this a wave of building/equipping/capacity-creation by others? The company provides a platform for data analysis. The customers are hospitals, labs, pharma. Are they building new capacity? Possibly labs are setting up new testing capabilities, like HRD testing. They mention "in-house HRD testing" with AstraZeneca partnership. They mention "expanding access to in-house HRD testing across European laboratories." That sounds like labs are building new testing capabilities. Also, they mention "newly launched HRD Solution" and "SOFIVA GENOMICS" as first clinical institution to offer it. They mention "demand in APAC for oncology applications." They mention "new customers in Japan, South Korea, Singapore, Hong Kong." They mention "GE partnership" to integrate data, and "commercial collaboration." They mention "CarePath" as new product. But does management convey that this build-out is early and big? They say "we are continuing to invest in our U.S.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| RDCM | RADCOM Ltd. | Q4 2023 | 2024-01-31 | A |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
TEL · Q4 2023 → YESThe question is about whether management explains the company's current momentum and near-term trajectory by pointing to a wave of new building or capacity-creation by others, that's early or intensif...YES The transcript shows management framing the company's momentum chiefly through a wave of external capacity creation: EV production growth (40% in 2023, expected continued growth next year, with Asia as driver), renewable energy adoption (wind/solar), and AI/cloud applications. They describe others (OEMs, installers 3rd parties) building new productive capability—new EV platforms, renewable sites, AI clusters—while TE already supplies into it via content outperformance and early ramps. Current business is real (sequential order growth, $1.3B pipeline, $100M+ incremental AI revenue). The wave is early/intensifying 2024–2025 (3–4 year programs, more phases ahead, destocking normalizing). This is presented as the primary secular driver offsetting cyclical weakness, not just consumption or pricing. Other elements (destocking, FX) are secondary. Thus all three conditions are met in substance.
ATI · Q1 2018 → YESThe question is about whether management explains the company's current momentum and near-term trajectory by pointing to a wave of new building or capacity-creation by other parties, like customers, t...YES The transcript shows management attributing HPMC momentum chiefly to the "ongoing production ramp of next-generation jet engines at all of our major engine OEM customers" and the "industry is currently in the early phases of a multi-year production expansion." This describes OEMs creating new productive capacity through rate ramps and build growth for next generation engines. Management confirms current business from this wave with "next-generation product sales reached 48% of total jet engine product sales" and "65% increase in next-generation product sales," plus "seventh consecutive quarter of year-over-year margin expansion.
RDCM · Q4 2023 → YESThe question is about whether management explains the company's current momentum and near-term trajectory by pointing to a wave of new building, equipping, or capacity-creation by other parties (custo...YES The transcript shows management framing 2024 momentum around operators’ ongoing 5G standalone network build-outs (new productive capacity being created by customers), with RADCOM already supplying assurance software to those projects and the wave described as still early and accelerating. All three conditions are met in Eyal Harari’s prepared remarks and Q&A.